Nanna Lüneborg joined Novo A/S in March 2012 and is Investment Director in Novo Seeds.

Nanna holds a 1st class BA from University of Oxford, a PhD in Neuroscience from University College London as a Wellcome Trust Scholar, and an MBA with distinction from University of Cambridge, where she was a Sainsbury Scholar.

Prior to joining Novo A/S, she was an Associate with Apposite Capital, a London-based healthcare venture fund, where she was responsible for diligence of new investment opportunities and involved in all aspects of investment activities, deal structuring and execution. She also gained experience in portfolio management through observer roles on three company boards, two of which were in drug development and one a medical device company. Earlier in her career, she worked at Cancer Research UK as a research manager, and worked as a consultant on various biotech and healthcare venture projects during her MBA. 

Nanna is on the Board of Directors of Affinicon, Glionova AB, , IO Biotech ApS, MinervaX and Pcovery,  and an observer on the Board of Directors of Galecto Biotech.